10-Q: Xenetic Biosciences Reports Second Quarter 2024 Financial Results, Royalty Revenue Up 11.6%

Xenetic Biosciences' second quarter 2024 results show an increase in royalty revenue but also a net loss, with a focus on advancing their DNase platform.

Summary

• Xenetic Biosciences reported a net loss of $1.27 million for the three months ended June 30, 2024, and a net loss of $2.47 million for the six months ended June 30, 2024.
• Royalty revenue increased by 11.6% to $726,404 for the quarter ended June 30, 2024, compared to $651,005 for the same period in 2023.
• For the six months ended June 30, 2024, royalty revenue was $1.24 million, slightly down from $1.26 million in the same period of 2023.
• Research and development expenses were $933,771 for the quarter and $1.88 million for the six months ended June 30, 2024.
• General and administrative expenses were $1.13 million for the quarter and $1.96 million for the six months ended June 30, 2024.
• The company's cash balance was $7.3 million as of June 30, 2024, compared to $9.0 million at the end of 2023.
• The company is focused on advancing its DNase platform into clinical trials for pancreatic carcinoma and other solid tumors.
• Xenetic has ongoing collaborations, including a royalty agreement with Takeda for its PolyXen technology.

Sentiment

Score: 4

Explanation: The document presents mixed signals. While there is positive growth in royalty revenue and ongoing collaborations, the significant net loss, high operating expenses, and need for future capital raise raise concerns. The company's future is dependent on the success of its DNase platform and its ability to secure additional funding.

Positives

• Royalty revenue saw a notable increase of 11.6% in the second quarter of 2024.
• The company maintains a cash balance of $7.3 million, providing some financial flexibility.
• Xenetic is actively progressing its DNase platform towards clinical trials, indicating potential future growth.
• The company has established collaborations with Takeda, Catalent, Scripps Research, and the University of Virginia.

Negatives

• The company experienced a net loss of $2.47 million for the first six months of 2024.
• Operating expenses, including research and development and general and administrative costs, remain high.
• The company's cash balance decreased from $9.0 million at the end of 2023 to $7.3 million as of June 30, 2024.
• The company has an accumulated deficit of $195.7 million as of June 30, 2024.

Risks

• The company has incurred substantial losses since its inception and expects to continue to incur operating losses in the near-term.
• The company anticipates it will need additional capital in the long-term to pursue its business initiatives.
• The capital markets for the biotech industry can be highly volatile, which make the terms, timing and extent of any future financing uncertain.
• The short and long-term implications of Russia's invasion of Ukraine and conflict in the Middle East are difficult to predict and may impact the company's operations.
• The company's ability to continue as a going concern is dependent on securing additional funding.

Future Outlook

The company anticipates needing additional capital in the long-term to pursue its business initiatives and is focused on advancing its DNase platform into clinical trials.

Management Comments

• Management believes that its existing resources will be adequate to fund the Company's operations for a period of at least twelve months from the date of the issuance of these financial statements.
• Management evaluates whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued.

Industry Context

The company is operating in the competitive biopharmaceutical industry, focusing on innovative immune-oncology technologies, particularly in the area of hard-to-treat cancers. The company's DNase platform is aimed at improving outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs).

Comparison to Industry Standards

• Xenetic's royalty revenue is dependent on the success of its partners, particularly Takeda, which is a common model in the biotech industry.
• The company's R&D spending is typical for a biotech company in the development stage, but the high operating losses and accumulated deficit are concerning.
• The company's cash burn rate is significant, and the need for additional capital is a common challenge for biotech companies in the clinical development phase.
• Compared to other biotech companies, Xenetic's focus on DNase and NETs is a niche area, which could provide a competitive advantage if successful.
• The company's collaborations with research institutions like Scripps and UVA are common strategies to advance technology development.

Management Changes

Related Party Transactions

• The company has entered into various research, development, license and supply agreements with Serum Institute and Pharmsynthez, each a related party.

Stakeholder Impact

• Shareholders may be concerned about the company's net losses and the need for additional capital.
• Employees may be affected by the management changes and the company's financial situation.
• Customers and partners may be impacted by the company's ability to continue its operations and development programs.
• Creditors may be concerned about the company's ability to repay its debts.

Next Steps

• The company will focus on advancing its DNase platform into clinical trials.
• The company will continue to seek additional funding through various means.
• The company will continue to engage in research and development activities with its collaborative partners.

Key Dates

Keywords

DNase platform, PolyXen technology, royalty revenue, biopharmaceutical, immune-oncology, clinical trials, pancreatic carcinoma, solid tumors, NETs, Takeda, biotech